The State Research Center “Vector” has applied for registration of the smallpox drug NIOCH-14. This has been reported DEA News”.
The publication states that on August 8, the incoming number of the drug was registered in the state drug registry.
According to Sergei Shchelkunov, Principal Investigator of the Division of Genomic Research at Rospotrebnadzor’s World Bank “Vector” Science Center, once NIOCH-14 enters medical practice, it will be effective against all types of orthopox viruses, including monkeypox. virus.
The agency states that the drug has successfully passed all phases of preclinical trials and the first phase of clinical trials on volunteers.
Former Deputy Director of Clinical and Analytical Studies of Rospotrebnadzor Natalya Pshenichnaya Central Research Institute of Epidemiology statedLong-term effects, including vision-related, are likely to occur after monkeypox.
According to the expert, if this virus gets into the eye, there is a risk of developing corneal inflammation (keratitis), which leads to its clouding, ulceration and future scarring, and as a result – irreversible loss. vision.